Comparative Effectiveness of Glimepiride versus Linagliptin as add-on to Metformin in Type-2-Diabetes Mellitus

Background: In addition to lifestyle modifications, metformin is the recommended first-line pharmacotherapy for patients with type 2 diabetes mellitus (T2DM). The use of glimepiride or linagliptin as add-on (GM LM) has been noticed on prescriptions in major pharmacies Nigeria.
 Aims: aim this study was compare efficacy T2DM.
 Methods: A preliminary case-crossover randomized experimental/observational comprising 30 participants (i.e., 15 each combination therapies) designed and designated GM LM groups, respectively. Baseline physiological health-indicators were primarily observed followed by a practical/analytical drug measurement postprandial blood glucose (PPBG) levels at 1, 2, 4, 6 h once weekly weeks thereafter crossover other regimen another two weeks’ assessment.
 Results: results consistent across subgroup analyses both treatment types. statistical analysis demonstrated that achieved significant PPBG lowering potential compared baseline status (p<0.05). There no difference biochemical indicators organ system function treatments during study. Treatment associated reduced post-meal Postprandial change over points higher (p<0.05).
 Conclusion: Blood control better GM. Propensity hypoglycemia LM. More studies involving larger patient population several centres are required validate outcome these findings.
 Keywords: Glimepiride, Linagliptin, Metformin, Fasting Glucose, glucose, Type Diabetes Mellitus